Your browser doesn't support javascript.
loading
Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome.
Esteve-Puig, Rosaura; Climent, Fina; Piñeyro, David; Domingo-Domènech, Eva; Davalos, Veronica; Encuentra, Maite; Rea, Anna; Espejo-Herrera, Nadia; Soler, Marta; Lopez, Miguel; Ortiz-Barahona, Vanessa; Tapia, Gustavo; Navarro, José-Tomás; Cid, Joan; Farré, Lourdes; Villanueva, Alberto; Casanova, Isolda; Mangues, Ramon; Santamarina-Ojeda, Pablo; Fernández, Agustín F; Fraga, Mario F; Piris, Miguel Angel; Kol, Nitzan; Avrahami, Chen; Moshitch-Moshkovitz, Sharon; Rechavi, Gideon; Sureda, Anna; Esteller, Manel.
Afiliación
  • Esteve-Puig R; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Climent F; Department of Pathology, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet, Barcelona, Spain.
  • Piñeyro D; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Domingo-Domènech E; Centro de Investigación Biomédica en Red (CIBER) de Cáncer (CIBERONC), Madrid, Spain.
  • Davalos V; Clinical Hematology Department, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain.
  • Encuentra M; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Rea A; Clinical Hematology Department, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain.
  • Espejo-Herrera N; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Soler M; Department of Pathology, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet, Barcelona, Spain.
  • Lopez M; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Ortiz-Barahona V; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Tapia G; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Navarro JT; Department of Pathology, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP) and.
  • Cid J; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Farré L; Department of Hematology, Catalan Institute of Oncology (ICO), Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
  • Villanueva A; Apheresis and Cellular Therapy Unit, Department of Hemotherapy and Hemostasis (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Casanova I; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Mangues R; Laboratory of Experimental Pathology (LAPEX), Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPQGM/FIOCRUZ), Salvador, Brazil.
  • Santamarina-Ojeda P; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Fernández AF; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Fraga MF; CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
  • Piris MA; Biomedical Research Institute Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Kol N; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
  • Avrahami C; CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
  • Moshitch-Moshkovitz S; Biomedical Research Institute Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Rechavi G; Nanomaterials and Nanotechnology Research Center-Spanish National Research Council (CINN-CSIC).
  • Sureda A; Health Research Institute of Asturias (ISPA).
  • Esteller M; Institute of Oncology of Asturias (IUOPA), and.
Blood ; 137(7): 994-999, 2021 02 18.
Article en En | MEDLINE | ID: mdl-32915956

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: ARN Neoplásico / Enfermedad de Hodgkin / Procesamiento Postranscripcional del ARN / Metilación de ADN / Colágeno Tipo I / Interferencia de ARN / Dioxigenasa Dependiente de Alfa-Cetoglutarato, Homólogo 3 de AlkB / Proteínas de Neoplasias Límite: Humans Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: ARN Neoplásico / Enfermedad de Hodgkin / Procesamiento Postranscripcional del ARN / Metilación de ADN / Colágeno Tipo I / Interferencia de ARN / Dioxigenasa Dependiente de Alfa-Cetoglutarato, Homólogo 3 de AlkB / Proteínas de Neoplasias Límite: Humans Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article País de afiliación: España